MAT Biopharma today announced the initiation of an escalating-dose Phase I/II study of the Company’s antibody Ferritarg P(R) in patients with relapsed or refractory Hodgkin’s disease.
EVRY, France | Mar 07, 2007 | MAT Biopharma today announced the initiation of an escalating-dose Phase I/II study of the Company’s antibody Ferritarg P(R) in patients with relapsed or refractory Hodgkin’s disease.
The study conducted in collaboration with Institut Curie will seek to enroll around 20 patients.
The goal of this study is to evaluate pharmacokinetic, the safety and the maximum tolerated dose (MTD) of Ferritarg P(R) in patients with Hodgkin’s disease.
In July 2006, FDA granted Orphan Drug Designation to MAT Biopharma’s Ferritarg P(R). This was an important step for MAT Biopharma’s ongoing effort to provide a new therapeutic option to patients afflicted by this disease.
"The initiation of this trial is an important milestone in the development of Ferritarg P(R) and has the potential to be a significant driver of the company’s future growth," said Jean Kadouche, Chief Executive Officer.
About Hodgkin’s disease
Hodgkin’s disease, also known as Hodgkin’s lymphoma, is a rare cancer of the lymphatic system. In Hodgkin’s disease, cells in the lymphatic system grow abnormally and may spread beyond the lymphatic system. As Hodgkin’s disease progresses, it compromises your body’s ability to fight infection.
Hodgkin’s disease most commonly affects people between the ages of 20 and 30 and people older than age 75. It’s one of two common types of cancers of the lymphatic system. According the American Cancer Society, in the United States in 2004, there were about 7,880 new cases of Hodgkin’s disease.
About MAT Biopharma.
MAT Biopharma is a privately held biopharmaceutical company focused on the development and commercialization of antibody based therapeutics for the treatment of haematological cancers and some solid tumors.
SOURCE: MAT Biopharma
Post Views: 191
MAT Biopharma today announced the initiation of an escalating-dose Phase I/II study of the Company’s antibody Ferritarg P(R) in patients with relapsed or refractory Hodgkin’s disease.
EVRY, France | Mar 07, 2007 | MAT Biopharma today announced the initiation of an escalating-dose Phase I/II study of the Company’s antibody Ferritarg P(R) in patients with relapsed or refractory Hodgkin’s disease.
The study conducted in collaboration with Institut Curie will seek to enroll around 20 patients.
The goal of this study is to evaluate pharmacokinetic, the safety and the maximum tolerated dose (MTD) of Ferritarg P(R) in patients with Hodgkin’s disease.
In July 2006, FDA granted Orphan Drug Designation to MAT Biopharma’s Ferritarg P(R). This was an important step for MAT Biopharma’s ongoing effort to provide a new therapeutic option to patients afflicted by this disease.
"The initiation of this trial is an important milestone in the development of Ferritarg P(R) and has the potential to be a significant driver of the company’s future growth," said Jean Kadouche, Chief Executive Officer.
About Hodgkin’s disease
Hodgkin’s disease, also known as Hodgkin’s lymphoma, is a rare cancer of the lymphatic system. In Hodgkin’s disease, cells in the lymphatic system grow abnormally and may spread beyond the lymphatic system. As Hodgkin’s disease progresses, it compromises your body’s ability to fight infection.
Hodgkin’s disease most commonly affects people between the ages of 20 and 30 and people older than age 75. It’s one of two common types of cancers of the lymphatic system. According the American Cancer Society, in the United States in 2004, there were about 7,880 new cases of Hodgkin’s disease.
About MAT Biopharma.
MAT Biopharma is a privately held biopharmaceutical company focused on the development and commercialization of antibody based therapeutics for the treatment of haematological cancers and some solid tumors.
SOURCE: MAT Biopharma
Post Views: 191
